- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02377921
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (GNEM)
June 11, 2019 updated by: Ultragenyx Pharmaceutical Inc
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid Extended-Release Tablets in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
The primary objective of this study is to evaluate the effect of 6 g/day aceneuramic acid extended-release (Ace-ER) treatment of participants with GNEM on upper extremity muscle strength (upper extremity composite [UEC] score) as measured by dynamometry.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
89
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sofia, Bulgaria
- UMHAT "Alexandrovska"
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N3Z5
- McMaster University
-
-
-
-
-
Paris, France
- Institut de Myologie GH Pitié-Salpêtrière
-
-
Reunion
-
Saint-Pierre, Reunion, France
- CHU La Réunion - site GHSR
-
-
-
-
-
Jerusalem, Israel
- Hadassah-Hebrew University Medical Center
-
-
-
-
-
Messina, Italy
- University of Messina
-
Milan, Italy
- University of Milan
-
Rome, Italy
- Università Cattolica
-
-
-
-
Tyne And Wear
-
Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE1 4LP
- The Newcastle Upon Tyne Hospitals
-
-
-
-
California
-
Irvine, California, United States, 92697
- University of California, Irvine
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New York
-
New York, New York, United States, 10016
- New York University School of Medicine
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, aged 18 to 55 years, inclusive
- Willing and able to provide written, signed informed consent after the nature of the study has been explained, and before any research-related procedures are conducted
- Have a documented diagnosis of GNEM, HIBM, distal myopathy with rimmed vacuoles (DMRV), or Nonaka disease due to previously demonstrated mutations in the gene encoding the GNE/N-acetylmannosamine kinase (MNK) enzyme (genotyping will not be conducted in this study)
- Able to provide reproducible force in elbow flexors (i.e. two dynamometry force values with no more than 15% variability in the dominant arm) at Screening
- Able to walk a minimum of 200 meters during the six-meter walk test (6MWT) at Screening without the use of assistive devices, including a cane, crutch(es), walker, wheelchair or scooter (ankle foot orthosis/orthoses are permitted)
- Willing and able to comply with all study procedures
- Participants of child-bearing potential or with partners of child-bearing potential who have not undergone a bilateral salpingo-oophorectomy and are sexually active must consent to use a highly effective method of contraception as determined by the site investigator (i.e. oral hormonal contraceptives, patch hormonal contraceptives, vaginal ring, intrauterine device, physical double-barrier methods, surgical hysterectomy, vasectomy, tubal ligation, or true abstinence [when this is in line with the preferred and usual lifestyle of the subject], which means not having sex because the subject chooses not to), from the period following the signing of the informed consent through 3 months after last dose of study drug
- Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause for at least two years, have had tubal ligation at least one year prior to Screening, or who have had a total hysterectomy or bilateral salpingo-oophorectomy
Exclusion Criteria:
- Ingestion of N-acetyl-D-mannosamine (ManNAc), sialic acid (SA), or related metabolites; intravenous immunoglobulin (IVIG); or anything that can be metabolized to produce SA in the body within 60 days prior to the Screening Visit
- History of more than 30 days treatment with SA-ER and/or Sialic Acid Immediate Release (SA-IR) in prior clinical trials in the past year
- Has had any hypersensitivity to SA or its excipients that, in the judgment of the investigator, places the subject at increased risk for adverse effects
- Has serum transaminase (i.e. aspartate aminotransferase [AST] or gamma-glutamyl transpeptidase [GGT]) levels greater than 3X the upper limit of normal (ULN) for age/gender, or serum creatinine of greater than 2X ULN at Screening
- Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study
- Use of any investigational product or investigational medical device within 30 days prior to Screening, or anticipated requirement for any investigational agent prior to completion of all scheduled study assessments
- Has a condition of such severity and acuity, in the opinion of the investigator, that it warrants immediate surgical intervention or other treatment or may not allow safe participation in the study
- Has a concurrent disease, active suicidal ideation, or other condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Aceneuramic Acid Extended-Release (Ace-ER)
Ace-ER 6 g/day, divided 3 times per day (TID) for 48 weeks.
|
tablets for oral use
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Matching placebo TID for 48 weeks.
|
tablets for oral use
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in UEC Score (Total Force in kg) at Week 48
Time Frame: Baseline, Week 48
|
Muscle strength based on the maximum voluntary isometric contraction (MVIC) against a dynamometer was measured bilaterally in the following upper extremity muscle groups: gross grip, shoulder abductors, elbow flexors, and elbow extensors.
The UEC is derived from the sum of the average of the right and left total force values (measured in kg).
|
Baseline, Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Muscle Strength in the Knee Extensors at Week 48
Time Frame: Baseline, Week 48
|
Lower extremity muscle strength in the knee extensors was measured by dynamometry.
Bilateral total force was defined as the average of the right and left force values (measured in kg).
|
Baseline, Week 48
|
Change From Baseline in LEC Score (Total Force in kg) at Week 48
Time Frame: Baseline, Week 48
|
Muscle strength based on MVIC against a dynamometer was measured bilaterally in the following lower extremity muscle groups: knee flexors, hip flexors, hip extensors, hip abductors and hip adductors.
The LEC is derived from the sum of the average of the right and left total force values (measured in kg).
|
Baseline, Week 48
|
Change From Baseline in GNEM FAS Mobility Domain Score at Week 48
Time Frame: Baseline, Week 48
|
Lower extremity use and function was assessed using the Mobility domain of the GNEM-FAS instrument a disease-specific measure developed to assess the functional impact of changes in muscle strength on mobility (reflective of the lower extremities).
This mobility score ranges from 0 to 40 with higher scores representing greater mobility.
|
Baseline, Week 48
|
Change From Baseline in Number of Lifts in the 30 Second Weighted Arm Lift Test at Week 48
Time Frame: Baseline, Week 48
|
Upper extremity function was assessed using a weighted arm lift test performed bilaterally.
The number of times the participant can raise a 1 kg weight above the head in a 30-second period was recorded.
|
Baseline, Week 48
|
Change From Baseline in Number of Stands in the Sit to Stand Test at Week 48
Time Frame: Baseline, Week 48
|
Lower extremity function was assessed using a sit-to-stand test.
The number of times the participant can rise from a seated to a standing position in a 30-second period was recorded.
|
Baseline, Week 48
|
Change From Baseline in Meters Walked in the 6MWT at Week 48
Time Frame: Baseline, Week 48
|
The total distance walked (meters) in a 6-minute period was measured.
|
Baseline, Week 48
|
Change From Baseline in Percent Predicted Meters Walked in the 6MWT at Week 48
Time Frame: Baseline, Week 48
|
The total distance walked (meters) in a 6-minute period was measured, and the percent predicted distance based on normative data for age and gender was estimated.
|
Baseline, Week 48
|
Change From Baseline in GNEM FAS Upper Extremity Domain Score at Week 48
Time Frame: Baseline, Week 48
|
Upper extremity use and function was assessed using the Mobility domain of the GNEM-FAS instrument a disease-specific measure developed to assess the functional impact of changes in muscle strength on mobility (reflective of the upper extremities).
This mobility score ranges from 0 to 40 with higher scores representing greater mobility.
|
Baseline, Week 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Tandon PK, Kakkis ED. The multi-domain responder index: a novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases. Orphanet J Rare Dis. 2021 Apr 19;16(1):183. doi: 10.1186/s13023-021-01805-5.
- Lochmuller H, Behin A, Caraco Y, Lau H, Mirabella M, Tournev I, Tarnopolsky M, Pogoryelova O, Woods C, Lai A, Shah J, Koutsoukos T, Skrinar A, Mansbach H, Kakkis E, Mozaffar T. A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy. Neurology. 2019 Apr 30;92(18):e2109-e2117. doi: 10.1212/WNL.0000000000006932. Epub 2019 Jan 25.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 20, 2015
Primary Completion (ACTUAL)
June 9, 2017
Study Completion (ACTUAL)
June 9, 2017
Study Registration Dates
First Submitted
February 27, 2015
First Submitted That Met QC Criteria
March 3, 2015
First Posted (ESTIMATE)
March 4, 2015
Study Record Updates
Last Update Posted (ACTUAL)
June 27, 2019
Last Update Submitted That Met QC Criteria
June 11, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UX001-CL301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Inclusion Body Myopathy
-
National Human Genome Research Institute (NHGRI)National Center for Advancing Translational Sciences (NCATS); Therapeutics...CompletedGNE Myopathy | Hereditary Inclusion Body Myopathy (HIBM)United States
-
Ultragenyx Pharmaceutical IncCompletedGNE Myopathy | Hereditary Inclusion Body Myopathy (HIBM)United States, Israel
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy (HIBM)United States
-
NobelpharmaCompletedGNE Myopathy | Nonaka Disease | Distal Myopathy With Rimmed Vacuoles (DMRV) | Hereditary Inclusion Body Myopathy (hIBM)Japan
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyCanada, United States, Bulgaria
-
Ludwig-Maximilians - University of MunichCompletedInclusion Body Myositis, Sporadic | Inclusion Body Myopathy, Autosomal-recessive | Inclusion Body Myopathy, Autosomal-dominant | Congenital Cataracts, Facial Dysmorphism, And NeuropathyGermany
-
Newcastle UniversityUnknownHereditary Inclusion Body Myopathy | GNE MyopathyUnited Kingdom
-
Tohoku UniversityCompletedHereditary Inclusion Body Myopathy | Nonaka MyopathyJapan
-
Ultragenyx Pharmaceutical IncTerminatedHereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing MyopathyUnited States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy | GNE MyopathyUnited States, Israel
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States